PXN: Key Enzyme for Post-Translational Modification of Prolyl Residues

Target Name: PXN

NCBI ID: G5829

Content of Review Report on PXN Target / Biomarker

PXN

PXN: Key Enzyme for Post-Translational Modification of Prolyl Residues

PXN (Prolyl hydroxylase N-acetyltransferase) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key enzyme in the hydroxylation of prolyl residues, which is a post- translational modification that involves the addition of an acetyl group to specific amino acids. This modification is important for the regulation of protein stability, localization, and interactions with other molecules.

PXN is a member of the PXN gene family, which includes several related proteins that share a conserved catalytic core but differ in their N-terminal and C-terminal regions. PXN is usually expressed in neurons and other dividing cells, and it has been implicated in the regulation of cell proliferation, differentiation, and survival.

One of the unique features of PXN is its ability to catalyze the hydroxylation of multiple prolyl residues in a single reaction. This is accomplished through a highly conserved catalytic core that includes a catalytic active site and several subunits that are involved in the transfer of the acetyl group. The N-terminal region of PXN includes a unique structural feature called a variable region, which is involved in the regulation of the activity of the enzyme and may function as a binding site for small molecules or other proteins.

PXN has been shown to play an important role in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown that PXN is expressed abnormally in the brains of individuals with these conditions and that the levels of PXN are often reduced in the brains of individuals with these diseases. Additionally, PXN has been shown to be involved in the regulation of cancer cell growth and survival, and it has been identified as a potential drug target for the treatment of various cancers.

In addition to its role in the regulation of neurodegenerative diseases and cancer, PXN has also been shown to have potential as a drug target for the treatment of other conditions. For example, PXN has been shown to be involved in the regulation of inflammation, and it has been identified as a potential target for the treatment of various inflammatory diseases. Additionally, PXN has been shown to be involved in the regulation of pain perception and the treatment of chronic pain, and it has been identified as a potential target for the treatment of chronic pain conditions.

Overall, PXN is a protein that has important roles in the regulation of various cellular processes that are important for the health and survival of cells. The unique structure and function of PXN make it an attractive target for the development of new drugs for the treatment of a variety of conditions. Further research is needed to fully understand the role of PXN in the regulation of cellular processes and to develop effective treatments for the various conditions that it is involved in.

Protein Name: Paxillin

Functions: Cytoskeletal protein involved in actin-membrane attachment at sites of cell adhesion to the extracellular matrix (focal adhesion). Recruits other proteins such as TRIM15 to focal adhesion

The "PXN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PXN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets